Evotec Expands Neuroscience Collaboration with Bristol Myers

  • Bristol Myers Squibb & Co BMY has expanded its neuroscience collaboration with Evotec SE EVTCY to include a new cell type.
  • Related: Bristol Myers Exercises Option In-License Evotec's Neurodegenerative Candidate.
  • The expansion has triggered a payment of $9 million to Evotec.
  • The collaboration was initiated in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. 
  • The collaboration pursues an approach to discovering and developing novel medicines by leveraging Evotec's iPSC platform using patient-derived disease models.
  • The latest expansion will enable the companies to investigate the root causes of many neurodegenerative diseases in a cell type-specific fashion using cells directly derived from patients. 
  • In addition, molecular disease signatures will be used to define detailed molecular disease phenotypes using Evotec's panomics platform, EVOpanOmics & EVOpanHunter.
  • Price Action: EVTCY stock closed at $90.38 on Thursday, while BMY stock is down 0.77% at $58.56 during the market session on the last check Friday.
BMY Logo
BMYBristol-Myers Squibb Co
$47.91-1.60%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
47.86
Growth
34.87
Quality
-
Value
16.58
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...